Recap: Enanta Pharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
Enanta Pharma (NASDAQ:ENTA) reported Q4 earnings with an EPS of $-1.33, beating the estimate by 33.5% against an expected $-2.0. However, revenue decreased by $1.39 million compared to the same period last year. In the previous quarter, despite beating the EPS estimate, the share price fell by 4.24% the following day.
November 20, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Enanta Pharma reported better-than-expected Q4 earnings but experienced a decline in revenue compared to last year. Historically, the stock dropped after a positive earnings surprise last quarter.
While Enanta Pharma beat the EPS estimates, the decline in revenue and the historical price drop following the last earnings beat suggest a potential negative short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100